Capital Impact Advisors LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 19.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 998 shares of the biotechnology company’s stock after selling 244 shares during the period. Capital Impact Advisors LLC’s holdings in United Therapeutics were worth $209,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Cookson Peirce & Co. Inc. raised its holdings in shares of United Therapeutics by 0.8% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 5,196 shares of the biotechnology company’s stock worth $1,088,000 after buying an additional 43 shares in the last quarter. Formidable Asset Management LLC lifted its holdings in shares of United Therapeutics by 2.2% in the third quarter. Formidable Asset Management LLC now owns 2,330 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 51 shares during the last quarter. Hancock Whitney Corp lifted its holdings in shares of United Therapeutics by 0.4% in the third quarter. Hancock Whitney Corp now owns 12,183 shares of the biotechnology company’s stock worth $2,550,000 after acquiring an additional 53 shares during the last quarter. Federated Hermes Inc. boosted its stake in shares of United Therapeutics by 0.5% in the 1st quarter. Federated Hermes Inc. now owns 13,603 shares of the biotechnology company’s stock valued at $2,441,000 after purchasing an additional 61 shares in the last quarter. Finally, Nicollet Investment Management Inc. grew its holdings in shares of United Therapeutics by 1.2% during the 2nd quarter. Nicollet Investment Management Inc. now owns 5,649 shares of the biotechnology company’s stock valued at $1,331,000 after purchasing an additional 69 shares during the last quarter. 95.63% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. UBS Group initiated coverage on shares of United Therapeutics in a research note on Tuesday, December 6th. They issued a “buy” rating and a $320.00 price objective for the company. StockNews.com assumed coverage on United Therapeutics in a research note on Thursday. They issued a “buy” rating for the company. Argus boosted their price objective on United Therapeutics from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, January 11th. JPMorgan Chase & Co. increased their target price on United Therapeutics from $265.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 23rd. Finally, HC Wainwright restated a “buy” rating and set a $300.00 price target on shares of United Therapeutics in a report on Thursday, February 23rd. Two equities research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $291.55.
United Therapeutics Price Performance
United Therapeutics (NASDAQ:UTHR – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The biotechnology company reported $2.67 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.12 by ($1.45). The business had revenue of $491.50 million during the quarter, compared to analyst estimates of $519.20 million. United Therapeutics had a net margin of 37.56% and a return on equity of 16.30%. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.35 earnings per share. On average, analysts expect that United Therapeutics Co. will post 17.95 earnings per share for the current year.
Insiders Place Their Bets
In related news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $222.63, for a total transaction of $1,781,040.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at approximately $28,941.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, January 19th. The stock was sold at an average price of $258.95, for a total transaction of $1,553,700.00. Following the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $9,425,003.15. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 9th. The shares were sold at an average price of $222.63, for a total value of $1,781,040.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at approximately $28,941.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 181,400 shares of company stock worth $46,782,673. Corporate insiders own 12.40% of the company’s stock.
United Therapeutics Profile
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
Featured Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
